14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RGNX vs RIGL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin), whereas RIGL carries 59.9/100 (HOLD) at $43.74 (9.3x Forward P/E, 26.3% operating margin).
Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment55.9% of Rev ($86M)
90D Engineering Disclosures0 Published
RIGL Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $860.3M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment44.4% of Rev ($128M)
90D Engineering Disclosures0 Published
Investor FAQ RGNX vs RIGL Key Questions & Quantitative Answers
As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin), whereas RIGL carries 59.9/100 (HOLD) at $43.74 (9.3x Forward P/E, 26.3% operating margin). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile RIGL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 42.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RIGL leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with RIGL at +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while RIGL shifted +625.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus 44.4% of Rev ($128M) (0 disclosures) for RIGL.
RIGL screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas RIGL trades at 9.3x Forward P/E, 2.8x Trailing P/E, N/M PEG, and 2.9x EV/Revenue (6.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus RIGL (109.2% ROE) capital efficiency.
In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk). By comparison, RIGL carries 61.2% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 74% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.